Afuco™ Anti-Human TNC ADCC Therapeutic Antibody (F16-131I), ADCC Enhanced
Anti-TNC ADCC Enhanced Antibody (F16-131I) is an ADCC enhanced antibody produced by our Afuco™ platform. The monoclonal antibodies F16-131I specific to F16 (specific to the A1 domain of tenascin-C) are currently investigated in Phase I and Phase II clinical trials in patients with cancer and with rheumatoid arthritis.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-600CL |
| Pricing | Inquiry |
| Host | Human |
| Target | TNC |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | IHC, FuncS, IF |
| Storage | ≤6 months at 4°C; ≥6 months at -20°C. |